A major program to create malaria vaccines has been stopped before Trump administrationIn just one example of disrupting ripples of health research around the world since the new US President took power.
Malaria vaccine development program, the United States Agency for International Development (MVDP-Which works to prevent the death of children by creating more effective vaccines than the second generation-the research conducted by the teams that cooperate through the institutes, including the University of Jones Hopkins and the University of Oxford in the United Kingdom.
Earlier this week, the partners were asked to stop working, after the president and his allies I command Freezing on us spending. The researchers have warned that the effect of sudden stopping on other programs can enhance the spread of drug -resistant HIV, and restore medical progress in the years.
The goal of MVDP is to “reduce malaria’s effect on children who live in the world’s malaria areas.” In almost sub -Saharan Africa in Africa 450,000 Under-5s We are Malaria every year.
while Introduction from two malaria vaccines In 2024 it was welcomed as a transformation, the MVDP research aims to make it more effective and longer.
One of the leading academics who participated in the program for several years said that the sudden pause would re -research, and it would have been likely to include continuous experiences in humans and animals.
They said that the projects funded by MVDP were often testing a new vaccine in humans for the first time, which means “huge effects of safety on the closure suddenly-you are completely obligated to follow up [participants] Up and make sure they stay in safety. “
Covering the orders of the American Winkfar 90 days While a review is made, according to official data.
However, multiple sources in the field of health research said that it is unclear who will have experience to implement such a review, as many senior officials of the American health bodies were launched.
Tom Drake, chief policy analyst at the Global Development Center, said that the impact of discounts on research financing was less clear and less urgent than The effects of providing life rescue programs All over the world “but not less realistic.”
“The appearance of malaria vaccines is one of the greatest global health achievements of our time, and it is a direct result of MVDP financing and many others,” he said.
“Even if the other financiers enter the gaps in financing the malaria vaccine, there is always the cost of an alternative opportunity, and therefore some other development research problem will be neglected as a result.”
Professor Kelly Chibal From the H3D Research Center at the University of Cape Town, he said that a project is to create a platform for the manufacture of active pharmaceutical components necessary for anti -virus in South Africa in danger.
He said: “We are urgently looking for alternative financing mechanisms to continue this important work, keeping the team members and ensuring the platform’s sustainability.” “The project will also suffer if our collaborators in the United States lose employees in this period of uncertainty.”
The researchers at Jomo Kenyatta of the University of Jumo Kenyatta for Agriculture and Technology in Kenya and the president -elect in the International Association of AIDS said that researchers in projects test the options for preventing HIV, such as injection and vaginal rings worldwide, have received work orders worldwide.
He said that even if the projects were returned after a 90 -day stop, there will remain “great harm.”
“It seems as if you were walking a car rushing on a highway. Then you apply emergency brakes. He said,” There are a lot of things that can get worse. “
“I have been researching the prevention of HIV over the past twenty years; nothing happened like this. The thing closest to this was Covid, and when Covid came, we were able to do so [find] Other ways to continue our programs. “
He said that some products, such as anti -HIV prevention drugs, are not yet available external research places, leaving participants who have no alternative source to continue treatment.
If the level of medications in the participant’s body decreases to non -protected levels, this does not only expose them to the risk of injury Developing drug resistance. This makes their treatment more complicated, and if they have someone else, the resistance will spread.
Nagor said that the recently completed projects and were ready to analyze data were affected. “Humans have given their time. It is also a moral commitment to you. When you perform a study, you need to finish this study and need to share results.”
He said: “There is a need to reconsider this decision. We have received great support from the United States government, and many injuries have been avoided, and we have now begun to talk about controlling the HIV in the coming years. If you stop, we start returning back. We can go back for many years, if not contracts.
He approached the comment, a Foreign Ministry spokesman pointed to a waiver On Wednesday for life -saving humanitarian assistance.
